Personalized Medicine Biomarkers Market Expansion via Pharma Investments

The global personalized medicine biomarkers market was valued at USD 21.88 billion in 2024 and is projected to reach USD 47.16 billion by 2030, growing at a CAGR of 13.6% from 2025 to 2030. Market growth is driven by the rising demand for personalized treatment regimens, the increasing prevalence of chronic diseases, and rapid advancements in diagnostic and detection technologies.

Biomarkers play a pivotal role in modern healthcare by enabling the early detection of diseases, improving survival rates, and reducing treatment costs. The increasing incidence of chronic illnesses, coupled with the growing adoption of precision medicine in oncology, cardiology, and other therapeutic areas, is significantly reshaping the healthcare landscape. According to the CDC’s February 2024 report, nearly 129 million people in the U.S. are living with at least one chronic illness, highlighting the urgent need for tailored treatment approaches. Additionally, as per the National Cancer Institute (NIH), approximately 9,620 children aged 0–14 are expected to be diagnosed with cancer in 2024, underscoring the importance of biomarkers in pediatric cancer detection and management.

Regulatory support is also strengthening market momentum. Agencies such as the U.S. FDA and the European Medicines Agency (EMA) are actively encouraging the development of companion diagnostics to ensure the safe and effective use of targeted therapies. This regulatory push, combined with greater awareness among healthcare providers and patients, is accelerating the adoption of biomarker-based personalized medicine.

Furthermore, the healthcare industry is increasingly embracing patient-centric models, placing a stronger focus on understanding individual biological profiles. This shift is fostering the development of precise diagnostics and therapeutics aimed at enhancing treatment efficacy while minimizing side effects. By tailoring interventions to individual patients, healthcare providers are not only improving clinical outcomes but also driving overall patient satisfaction.

Key Market Highlights

• North America dominated the global market, accounting for 51.93% revenue share in 2024.
• The U.S. held a significant share of the North American market in 2024.
• By application, the treatment selection segment led with 50.2% share in 2024.
• By indication, the oncology segment dominated with a 35.0% share in 2024.

Download a free sample PDF of the Personalized Medicine Biomarkers Market Intelligence Study from Grand View Research.

Market Performance

• 2024 Market Size: USD 21.88 Billion
• 2030 Projected Market Size: USD 47.16 Billion
• CAGR (2025–2030): 13.6%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Prominent Companies & Market Dynamics

The market is highly competitive, with companies focusing on new product launches, mergers and acquisitions, and regional expansion to strengthen their global presence. Diversification of product portfolios to cover broader applications is a key strategy among players.

Key Companies

• Laboratory Corporation of America Holding
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.
• Genome Medical, Inc.
• Coriell Life Sciences
• Thermo Fisher Scientific Inc.
• NeoGenomics Laboratories
• Foundation Medicine, Inc.
• Illumina, Inc.
• Guardant Health

Explore Global Industry Herald for Insights that Drive Smarter Decisions

Conclusion

The personalized medicine biomarkers market is experiencing robust growth, fueled by the rising prevalence of chronic diseases, technological advancements in diagnostics, and increasing regulatory support for precision medicine. While North America remains the largest market, the Asia Pacific region is emerging as the fastest-growing hub due to rising healthcare investments and expanding access to advanced diagnostics. As healthcare systems continue to prioritize individualized treatment approaches, biomarkers are set to play a central role in advancing precision medicine, improving patient outcomes, and reducing overall healthcare costs worldwide.